This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts

BayerPRO Case Studies | PP-PF-OTH-GB-0077, August 2024

PP-PF-OTH-GB-0077 | August 2024

nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Urologist Perspective
PP-NUB-GB-2038, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Clinical Nurse Specialist Perspective
PP-NUB-GB-2046, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Pharmacist Perspective
PP-NUB-GB-2028, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - An Oncologist Perspective
PP-NUB-GB-2031, January 2025
mCRPC Patient Case Study
A Nuclear Medicine perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0575, June 2024
mCRPC Patient Case Study
An Oncologist Perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0574, June 2024